

SUBJECT INDEX VOLUME 27

A

5-HT receptors, 171
 5-HT, 869
 5-HT_{1A} agonist, 421
 5-HT_{1A} antagonist, 421
 5-HT_{1A} receptor agonism, 430
 5-HT_{1A} receptor knockout mice, 380
 5-HT_{1A} Receptors, 301
 5-HT_{1A} Receptors, 349
 5-HT_{2A} and 5-HT_{2C} receptors, 576
 5-HT_{2A} receptor antagonism, 430
 5-HT_{2C} receptor antagonism, 430
 8-OH-DPAT, 993
 Acamprosate, 596
 Acetylcholine, 182
 Acetyl-L-carnitine, 410
 ACPC, 727
 ACTH, 442, 470
 Addiction, 727, 889, 924, 1027
 Adenosine, 629
 Adolescence, 212
 Adults, 655
 Affective disorders, 638, 792, 874
 Aggression, 171, 646
 Aging, 663
 Alcohol, 596
 Alprazolam, 260
 Alzheimer's disease, 646
 Amidation, 55
 Amino acids, 852
 Amisulpride, 1071
 Amitriptyline, 554
 AMPA, 826
 Amphetamine, 225, 930, 970, 1036
 Amygdala, 1036
 Anandamide, 980
 Animal model, 1
 Anpirtoline, 171
 Antidepressant drug development, 319
 Antidepressant drugs, 357
 Antidepressant response, 120
 Antidepressant treatment, 874
 Antidepressant, 237, 319, 587, 914, 939, 949
 Antipsychotic agents, 906
 Antipsychotic drugs, 105
 Antipsychotic, 1, 691, 930, 1071
 Antisaccade, 1056
 Antisense oligodeoxyribonucleotides, 554
 Anxiety, 25, 85, 194, 357, 371, 380, 782, 1036
 Anxiolytic drugs, 357
 Apomorphine, 980
 Applied psychology, 279
 Aripiprazole, 248
 Assay, 663
 Association regions, 672
 Associative, 924
 Atomoxetine, 699
 Attention deficit hyperactivity disorder, 607, 655, 699
 Attention deficit, 400
 Attention, 712, 993
 Atypical antipsychotic, 1071
 Auditory, 862
 Augmentation, 620, 906

Autoimmune disorders, 939
 Autoradiography, 826
 Autoreceptors, 301
 Axiolytic, 194

B

Basal ganglia, 92, 143, 453
 Basolateral nucleus of the amygdala, 744
 BDNF mRNA, 133
 Bed nucleus of stria terminalis, 25
 Behavior, 380, 691, 813
 Behavioral and psychological symptoms of dementia, 646
 Benzodiazepines, 357
 Bipolar disorder, 620, 792, 834
 Bradykinesia, 684
 Brain, 92, 309, 672

C

Caffeine, 182
 Calcium, 565
 cAMP, 939
 Candidate genes, 607
 Carbenoxolone, 980
 Cat, 72
 Catecholamine, 293
 Caudate-putamen, 143
 Cholecystokinin, 663
 Cingulate cortex, 826
 Clearance, 293
 Clinical methodology, 319
 Clinical response, 1050
 Clinical trial, 319
 Clomipramine, 554
 Clozapine, 143, 152, 534, 1050
 Cocaine abuse, 35
 Cocaine, 542, 576, 970
 Cognition, 596
 Cognitive function, 479
 Componential behavioral approach, 319
 Conditioning, 203, 225, 518, 924, 1006
 Connectivity, 672
 Context, 1006
 Cordance, 120
 Corticosterone, 756
 Cortisol, 309, 442, 470, 834, 1041
 Craving, 924
 CREB, 565
 CRF, 194
 CRH, 756
 Cross-sensitization, 970
 Current density, 638
 Cyclic AMP, 587
 Cytoskeleton, 55

D

D₁ Dopamine receptor, 970
 D₁ receptors, 35
 D₂ dopamine receptor, 248

D₂ receptor isoforms, 723
 D₂ receptors, 35, 72
 d-Amphetamine, 813
 D-cycloserine, 906
 Delayed alternation, 47
 Dentate gyrus, 133
 Depression, 12, 120, 792, 852, 914, 939
 Depressive disorder, 1041
 Desipramine, 914
 Development, 47, 309, 672
 DEX/CRH Test, 470
 DHPG, 293
 Diazepam, 380
 Dopamine, 35, 72, 92, 163, 182, 410, 518, 565, 691, 699, 889, 949, 1036
 Dopamine agonist, 248
 Dopamine D₃ receptors, 105
 Dopamine receptors, 607
 Dopamine release, 430
 Dopamine transporter, 607
 Dopamine transporter gene, 655
 Dorsal raphe nucleus, 349
 Dorsolateral prefrontal cortex, 638
 Driving, 260
 Drug aversion, 727
 Drug pre-exposure, 970
 Drug reward, 727
 Drug self-administration, 1006
 Drugs of abuse, 565
 Dual diagnosis, 889

E

ECT, 55
 EEG, 120
 EEG topography, 462
 Electroencephalography, 1016
 Electrophysiology, 723
 Elevated plus-maze, 357, 371
 Elk-1, 565
 EPSC, 329
 ERK, 565
 Escape deficit, 410
 Estradiol, 800
 Estrogen, 12
 Estrus cycle, 85
 Ethanol, 391, 442
 Event related potentials, 629
 Event-related magnetic field, 862
 Eye movements, 1056

F

Family history, 834
 Family history of alcoholism, 442
 Fear, 357, 744, 1036
 Flesinoxan, 380
 Fluoxetine, 914
 fMRI, 282
 Footshock stress, 133
 Fos expression, 699

Fos, 565
 Fox odor, 744
 Free-choice drinking, 212
 Frontal cortex, 203
 Frontal, 672
 Frustration, 171
 Fusiform, 282

G

G proteins, 499
 GABA_B receptors antagonist, 960
 Galanin, 25, 349
 Gamma-hydroxybutyrate, 960
 Gap junction, 980
 GEF, 55
 Gene knockout, 587
 Gene knockout mouse, 914
 Genetics, 655
 Gerbil, 357, 371
 Gi-proteins, 554
 Glucocorticoid, 309
 Glutamate, 906
 Glutamatergic neuron, 329
 GR127935, 171
 Grooming, 930, 980
 Growth hormone, 301, 1041

H

Haloperidol, 143, 152, 430, 534, 684, 930
 Hamilton Depression Rating Scale, 852
 Handling stress, 163
 Haplotype-based haplotype relative risk, 607
 Herbal medicine, 279
 Hippocampal slices, 960
 Hippocampus, 1, 133, 349, 889, 930
 Hormone replacement therapy, 12
 HPA axis, 25, 442
 HPA system, 470
 Human, 499, 800, 813
 Hyperactivity, 400
 Hyperthermia, 380
 Hyperventilation, 85
 Hypothalamic-pituitary-adrenal axis, 939
 Hypothalamus, 301

I

Immunolabeling, 499
 Imprinting, 607
 Impulsive behavior, 421
 Impulsivity, 171, 813
 In situ hybridization, 152, 906
 In vivo microdialysis, 237
 Intracellular recordings, 960
 Ipsapirone, 270

K

Kainate receptors, 826
 Ketanserin, 993
 Knock-out, 869

L

Lithium, 756
 Lithium augmentation, 470
 Locomotion, 576, 930
 Locomotor activity, 349
 Lorazepam, 282
 L-thyroxine, 620

M

M40, 25
 Magnetic resonance imaging, 792
 Magnetoencephalography (MEG), 862
 Maintenance treatment, 620
 Major depression, 470, 638
 Male rats, 133
 Maternal deprivation, 756
 Maternal separation, 518
 mCPP, 993
 MDMA, 993
 Medial prefrontal cortex, 163, 430, 744
 Medication resistance, 638
 Memory, 260, 279, 534, 993
 Mesolimbic, 518
 Methamphetamine, 453
 Methylphenidate, 163, 400, 699
 Mice, 212, 587
 Microdialysis, 163, 182, 349, 691, 699, 949
 Middle-latency auditory magnetic field (MAEF), 862
 Molecular genetics, 105
 Monoamines, 237, 1036
 Monoamine oxidase inhibitors (MAOI), 462
 Mood, 834, 852
 Mood disorders, 792, 939, 1016
 Morphine, 518
 Motor activity, 980
 Movement disorder, 92
 mRNA, 499
 Multiple drug resistance pump, 939
 Myelin, 672

N

Naloxonazine, 391
 Naltrexone, 391, 596
 Naltrindole, 391
 Natural reward, 727
 NCS-382, 960
 Negative symptoms, 479
 Neonatal lesion, 1, 47
 Neural networks, 672
 Neuroactive steroids, 874
 Neurochemical pathology, 646
 Neuroendocrinology, 470
 Neuroimaging, 782, 792
 Neurokinin, 329
 Neurokinin NK1 receptor, 371
 Neurokinin-1-receptor, 1041
 NGFI-B, 400
 Nicotine, 212, 270, 479, 534, 684, 712, 1056
 NK₁ receptor antagonists, 371
 NK₁ receptors, 329
 NMDA, 826
 NonREM, 869
 Noradrenaline, 691
 Norepinephrine, 163, 699, 949
 Novelty seeking, 225
 Novelty, 380
 NPY, 55, 756
 Nucleus accumbens, 35, 182,, 430, 889, 1027
 Nucleus accumbens shell, 410

O

Occasion setting, 1006
 Olanzapine, 143
 Olfactory tubercle, 203
 Ondansetron, 542
 Onset of drug action, 319
 Opioid antagonists, 391
 Opioid peptide, 203
 Opioids, 518
 Opponent processes, 542

Oral behaviors, 980
 Oral self-administration, 212
 Orbitofrontal cortex, 782

P

P50, 629
 Panic attacks, 663
 Panic disorder, 85, 270
 Parkinson's disease, 723
 Pavlovian, 924
 Performance, 260
 Pertussis toxin, 554
 Pharmacodynamics, 596
 Pharmacogenetics, 105
 Pharmacogenomics, 105
 Pharmacokinetics, 596
 Phosphodiesterase 4D (PDE4D), 587
 Pigeon, 421
 Pituitary-adrenal, 194
 Place conditioning, 727
 Plasma concentration, 663
 Plasma levels, 1050
 Positron Emission Tomography (PET), 72, 248, 782
 Posterior cingulate cortex, 782
 Postmortem brain, 499
 Prefrontal, 120
 Prefrontal cortex, 47, 182, 874
 Premenstrual dysphoria, 85
 Prepulse inhibition, 1, 400, 765
 Primate, 12
 Priming, 282
 Progesterone, 12, 800
 Progressive ratio schedule of reinforcement, 970
 Prolactin, 301, 800
 Prophylaxis resistance, 620
 Proton magnetic resonance spectroscopy, 453
 Psychological stress, 133
 Psychology, 279
 Psychomotor, 260
 Psychopharmacology, 279, 282
 Purinergic system, 629

Q

Quantitative Trait Analysis, 655
 Quantitative Trait Locus (QTL), 765

R

[¹¹C]raclopride, 72, 248
 Raclopride, 1006
 Radial-arm maze, 534
 Radiotelemetry, 380
 Raphe, 329
 Rat, 85, 712, 727, 756
 Reboxetine, 237, 699
 Receptor binding, 663
 Receptor occupancy, 248
 Recombinant congenic mouse strains, 765
 Regional differences, 462
 Reinforcement, 171, 1027
 Reinstatement, 1006
 Relapse, 391, 1006
 REM sleep, 462, 843, 1016
 Response prediction, 120
 Reuptake, 237
 Reward, 1027
 R-Fluoxetine, 949
 Rhesus monkey, 35
 Rigidity, 684
 Risperidone, 143, 534, 1071

RNA messenger, 906
Rolipram, 587

S

SCH 23390, 970, 1006
Schizoaffective disorder, 620
Schizophrenia, 1, 105, 143, 152, 248, 293, 309, 479, 629, 672, 684, 723, 765, 826, 889, 1050, 1056, 1071
Scopolamine, 282
Self-administration, 542, 576, 970
Sensitization, 225, 542, 924, 970
Sensorimotor gating, 765
Sensory gating, 629
Serial reaction time, 712
Serotonergic reuptake inhibitor, 782
Serotonin, 12, 171, 270, 301, 329, 349, 410, 576, 646, 800, 834, 843, 852, 862, 949, 1016
Serotonin transporter, 914
Short-term memory, 279
Single nucleotide polymorphism, 105
Sleep, 843, 869, 1041
Sleep deprivation, 869
Slow-wave activity, 462
Smoking, 270, 479
Smooth pursuit, 1056
Sniffing stereotypy, 980
Social instigation, 171
Sodium lactate, 85

Spillover, 293
SSRI, 421
Startle response, 765
State dependence, 727
Stereology, 143
Stimulation intensity, 638
Stress, 25, 194, 203, 237, 309, 410, 442, 756
Stress-induced hyperthermia, 380
Striatum, 35, 92
Subjective Effect, 813
Substance P, 1041
Substantia nigra, 723
Sucrose, 171
Suicide, 499
Supraphysiological, 620
Sustained attention, 1056

T

Tachycardia, 380
Tachykinin, 371
Tardive dyskinesia, 105
Temporal, 672
Testosterone, 800
Theophylline, 629
Theta activity, 462
TMS, 874
Tolerance, 712
Tourette syndrome, 92
Transcranial magnetic stimulation, 638, 874

Transcription factors, 152
Transgenic, 869
Transmission Disequilibrium Test, 607
Tremor, 684
Tricyclic antidepressants, 554
Tritium-labeled norepinephrine, 293
Tryptophan, 843
Tryptophan depletion, 834, 852, 862
Tumor necrosis factor alpha, 939

U

Unipolar disorder, 792
Unipolar major depressive disorder, 620

V

Ventral hippocampus, 47
Ventral tegmental area, 723, 744, 970
Voltammetry, 72

W

Weaning, 225
White matter, 672
Withdrawal, 203, 542
Working memory, 47